ClinicalTrials.gg
RecruitingNCT04740697EUTACAMUpdated Apr 20, 2026

Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer

An interventional study of Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen. in Breast Cancer, sponsored by Institut Claudius Regaud. Recruiting at 1 site in France. Open to female participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2026-04-20.

Sponsored by Institut Claudius Regaud · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Months and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Breast Neoplasms by Institut Claudius Regaud — 6 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut Claudius Regaud.

Planned enrollment
8th of 23
200 · median 120
Started
2021
with 1 other
No phase
12 of 26
4 open now
Registered
18th of 26
by date

Among the 26 studies in Breast Neoplasms by Institut Claudius Regaud, this one is the 8th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2021, is one of 12 with no phase, and was the 18th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 26 studies in Breast Neoplasms by Institut Claudius Regaud are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Months and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Breast Neoplasms by Institut Claudius Regaud, or all of them as a file.
02

Study summary

This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients with localized hormone-dependent breast cancer.

200 patients will be included in the study.

Each patient will be followed for one day.

03

Conditions studied

  • Breast Cancer

Keywords

  • Breast Cancer
  • Tamoxifen
  • Alternative and complementary therapies
  • Treatment adherence
  • Turmeric
04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years at entry into the study.
  2. Patient treated for hormone-dependent localized breast cancer requiring Hormonal Therapy (HT) with tamoxifen.
  3. Patients treated with tamoxifen for a maximum of 1 to 3 years.
  4. Patient affiliated with a Social Security system in France.
  5. Patients who signed prior to inclusion in the study and prior to any specific study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding women.
  2. Any psychological, family, geographical or sociological condition that does not allow the medical follow-up and/or the procedures foreseen in the study protocol to be respected.
  3. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    Patient with localized breast cancer.

    Other: Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.

Interventions

  • OtherTreatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.

    Each included patient will be referred to the health care staff for a blood sample: * for the determination of the residual plasma concentration of tamoxifen and its active metabolites, * for the constitution of a biobank. Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...).

06

What researchers measure

Primary outcomes

  1. Rate of patients who adhere to tamoxifen treatment.

    This outcome will be assessed by the completion of the GIRERD questionnaire by the patient.

    Time frame: 18 months after the start of the research

Secondary outcomes

  1. Rate of patients taking ACT.

    Time frame: 18 months after the start of the research

  2. Rate of patients consuming turmeric-based dietary supplements.

    Time frame: 18 months after the start of the research

  3. Plasma concentration of tamoxifen in patients.

    Time frame: 18 months after the start of the research

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Feb 2028, 84 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 84 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2021
First posted
Feb 5, 2021
StartActual
Feb 12, 2021
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Apr 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04740697
Responsible party
Sponsor
First posted
Feb 5, 2021
Start date
Feb 12, 2021
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Apr 20, 2026

Study contacts

Florence DALENC
Contact
dalenc.florence@iuct-oncopole.fr
05 31 15 51 04

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion